UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Hyperbaric Oxygen Therapy for Radiation-Induced Cystitis and Proctitis

International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (3), p.733-740

2012

Volltextzugriff (PDF)

Clinical features of pseudocirrhosis in metastatic breast cancer

Breast cancer research and treatment, 2019-09, Vol.177 (2), p.409-417

2019

Volltextzugriff (PDF)

Radioprotectants to reduce the risk of radiation-induced carcinogenesis

International journal of radiation biology, 2014-03, Vol.90 (3), p.203-213

2014

Volltextzugriff (PDF)

How to address second and therapy‐related acute myelogenous leukaemia

British journal of haematology, 2020-01, Vol.188 (1), p.116-128

2020

Volltextzugriff (PDF)

Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL

Leukemia research reports, 2021-01, Vol.16, p.100260, Article 100260

2021

Volltextzugriff (PDF)

Dendritic cells and CD28 costimulation are required to sustain virus-specific CD8+ T cell responses during the effector phase in vivo

The Journal of immunology (1950), 2011-04, Vol.186 (8), p.4599-4608

2011

Volltextzugriff (PDF)

Transient SARS-CoV-2 RNA-Dependent RNA Polymerase Mutations after Remdesivir Treatment for Chronic COVID-19 in Two Transplant Recipients: Case Report and Intra-Host Viral Genomic Investigation

Microorganisms (Basel), 2023-08, Vol.11 (8), p.2096

2023

Volltextzugriff (PDF)

Effectiveness of Single-Fraction, Low-Dose, Bilateral Whole Lung Radiation Therapy for Diffuse Alveolar Hemorrhage Secondary to Extramedullary Hematopoiesis: A Case Report and Review of the Literature

Advances in radiation oncology, 2024-07, Vol.9 (7), p.101506, Article 101506

2024

Volltextzugriff (PDF)

Case Report: Sustained Remission Achieved from Anti-CD19 CAR T Cell Therapy Despite Prior Treatment with Anti-CD19 Antibody Tafasitamab (MOR208) in a Patient with Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Blood, 2019-11, Vol.134 (Supplement_1), p.5360-5360

2019

Volltextzugriff (PDF)

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Secondary Central Nervous System Lymphoma

Blood, 2021-11, Vol.138 (Supplement 1), p.4911-4911

2021

Volltextzugriff (PDF)

Outcomes of allogeneic hematopoietic stem cell transplantation in secondary central nervous system lymphoma: a case series

Leukemia & lymphoma, 2023-01, Vol.64 (2), p.507-510

2023

Volltextzugriff (PDF)

SBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines

Frontiers in oncology, 2014-01, Vol.4, p.312-312

2014

Volltextzugriff (PDF)

Intravenous IL-1 Receptor Antagonist for Prevention of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome

Blood, 2023-11, Vol.142 (Supplement 1), p.4858-4858

2023

Volltextzugriff (PDF)

Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia

Current treatment options in oncology, 2018-12, Vol.19 (12), p.63-63, Article 63

2018

Volltextzugriff (PDF)

Liposomal Cytarabine-Daunorubicin (CPX-351) Extravasation: Case Report and Literature Review

Anticancer research, 2018-12, Vol.38 (12), p.6927-6930

2018

Volltextzugriff (PDF)

Delayed immune tolerance through donor haematopoietic stem cell infusion 14 months after kidney transplantation

The Lancet (British edition), 2024-10, Vol.404 (10460), p.1346-1346

2024

Volltextzugriff (PDF)

Trial in Progress: Tagraxofusp-Based Therapy to Eradicate Measurable Residual Disease of Acute Myelogenous Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation

Blood, 2022-11, Vol.140 (Supplement 1), p.6230-6232

2022

Volltextzugriff (PDF)

Trial in Progress: Acalabrutinib Maintenance Following Cellular Therapy for Large B-Cell Lymphoma Patients at High Risk for Relapse

Blood, 2022-11, Vol.140 (Supplement 1), p.12735-12736

2022

Volltextzugriff (PDF)

Outpatient Vyxeos Induction without Planned Admission for Select Patients with Secondary Acute Myeloid Leukemia (sAML): A Multicenter Analysis of Safety and Healthcare Resource Utilization

Blood, 2022-11, Vol.140 (Supplement 1), p.3320-3321

2022

Volltextzugriff (PDF)

Real World Outcomes of Patients with Secondary Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation after Induction with Liposomal Daunorubicin-Cytarabine (CPX-351)

Blood, 2023-11, Vol.142 (Supplement 1), p.5938-5938

2023

Volltextzugriff (PDF)

Deliriogenic Medication Use in Older Adults Receiving CAR-T Correlates with Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Blood, 2023-11, Vol.142 (Supplement 1), p.7358-7358

2023

Volltextzugriff (PDF)

Reconsidering the Significance of Blast Cut-Offs in Differentiating between MDS and AML Biology

Blood, 2023-11, Vol.142 (Supplement 1), p.1884-1884

2023

Volltextzugriff (PDF)

Decreased Chimeric Antigen Receptor T-Cell Efficacy with Severe or Prolonged Post-Infusion Cytopenias

Blood, 2021-11, Vol.138 (Supplement 1), p.3869-3869

2021

Volltextzugriff (PDF)

Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL

Journal of clinical oncology, 2024-10

2024

Volltextzugriff (PDF)

High Disease-Free Survival in Patients with High-Risk MDS Treated with Orca-T

Blood, 2023-11, Vol.142 (Supplement 1), p.2230-2230

2023

Volltextzugriff (PDF)

1 – 25 von 85

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(77)

Publikationsform

Artikel
(82)
Berichte
(3)

Sprache

Englisch
(85)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Hyperbaric Oxygen Therapy for Radiation-Induced Cystitis and Proctitis

Clinical features of pseudocirrhosis in metastatic breast cancer

Radioprotectants to reduce the risk of radiation-induced carcinogenesis

How to address second and therapy‐related acute myelogenous leukaemia

Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL

Dendritic cells and CD28 costimulation are required to sustain virus-specific CD8+ T cell responses during the effector phase in vivo

Transient SARS-CoV-2 RNA-Dependent RNA Polymerase Mutations after Remdesivir Treatment for Chronic COVID-19 in Two Transplant Recipients: Case Report and Intra-Host Viral Genomic Investigation

Effectiveness of Single-Fraction, Low-Dose, Bilateral Whole Lung Radiation Therapy for Diffuse Alveolar Hemorrhage Secondary to Extramedullary Hematopoiesis: A Case Report and Review of the Literature

Case Report: Sustained Remission Achieved from Anti-CD19 CAR T Cell Therapy Despite Prior Treatment with Anti-CD19 Antibody Tafasitamab (MOR208) in a Patient with Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Secondary Central Nervous System Lymphoma

Outcomes of allogeneic hematopoietic stem cell transplantation in secondary central nervous system lymphoma: a case series

SBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines

Intravenous IL-1 Receptor Antagonist for Prevention of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome

Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia

Liposomal Cytarabine-Daunorubicin (CPX-351) Extravasation: Case Report and Literature Review

Delayed immune tolerance through donor haematopoietic stem cell infusion 14 months after kidney transplantation

Trial in Progress: Tagraxofusp-Based Therapy to Eradicate Measurable Residual Disease of Acute Myelogenous Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation

Trial in Progress: Acalabrutinib Maintenance Following Cellular Therapy for Large B-Cell Lymphoma Patients at High Risk for Relapse

Outpatient Vyxeos Induction without Planned Admission for Select Patients with Secondary Acute Myeloid Leukemia (sAML): A Multicenter Analysis of Safety and Healthcare Resource Utilization

Real World Outcomes of Patients with Secondary Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation after Induction with Liposomal Daunorubicin-Cytarabine (CPX-351)

Deliriogenic Medication Use in Older Adults Receiving CAR-T Correlates with Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Reconsidering the Significance of Blast Cut-Offs in Differentiating between MDS and AML Biology

Decreased Chimeric Antigen Receptor T-Cell Efficacy with Severe or Prolonged Post-Infusion Cytopenias

Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL

High Disease-Free Survival in Patients with High-Risk MDS Treated with Orca-T

Suchergebnisse filtern